SB 220025

Reference compound

p38 MAPK; PKC; Src

-20°C, 3 years; 4°C, 2 years (Powder)

SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM). SB 220025 also inhibits p56Lck and PKC with IC50 values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation[1][2].

DMSO: 50 mg/mL (ultrasonic; warming; heat to 60°C)

Lck; p38 MAPK; PKC